National Institutes of Health

Allyx Therapeutics, founded in 2018 and based in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company’s primary product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative drug aims to reverse neurodegeneration and offers a potential approach to preserve cognitive function in patients with Alzheimer's. By targeting the underlying mechanisms of the disease, Allyx Therapeutics strives to provide effective therapeutic solutions for those affected by neurodegenerative disorders.

Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company founded in 2011 and located in Winchester, Massachusetts. The company focuses on developing immune-based therapies for cancer and chronic infectious diseases. A key aspect of its research involves targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and addressing the specific population of TNFR2 regulatory T cells present in the tumor microenvironment. Through its innovative approaches, Boston Immune Technologies aims to advance immunotherapy options for patients facing these challenging health conditions.

MaineHealth is a not-for-profit family of leading high-quality providers and other healthcare organizations working together so our communities are the healthiest in America. Ranked among the nation's top 100 integrated healthcare delivery networks, MaineHealth member organizations include Maine Medical Center, Franklin Community Health Network, LincolnHealth, Maine Behavioral Healthcare,

Barrett Technology, LLC, established in 1990 and located in Newton, Massachusetts, specializes in the design and manufacture of advanced robotic manipulators. The company has developed pioneering technology that enhances the flexibility of articulated arms and hands, positioning itself as a leader in the field. Barrett's innovative manipulators have earned recognition, including a place in the Guinness Book of World Records, for their superior capabilities. The company's products offer exceptional versatility, making them suitable for a wide range of applications across various industries.

Aphios Corporation is a biotechnology company based in Woburn, Massachusetts, specializing in drug delivery and manufacturing technologies. Founded in 1993, Aphios develops innovative platforms that enhance drug discovery and ensure the safety of pharmaceuticals. The company focuses on creating therapeutic products aimed at health maintenance, disease prevention, and treatment of various conditions, including cancers, infectious diseases, and central nervous system disorders. Notable products include Zindol, a ginger-derived therapeutic, and several advanced formulations such as APH-0703, a protein kinase C activator, and APH-0911, a nanotechnology-based prodrug for cancer treatment. Additionally, Aphios is engaged in developing technologies related to supercritical fluids for the production of natural pharmaceuticals, as well as specialized equipment for various applications, including microbial cell disruption and biomass pretreatment for biofuels. The company also provides virology testing services to validate viral clearance and inactivation.

Sapphiros is a private equity growth and expansion firm founded in 2021 and based in Massachusetts. The company specializes in investing in growth-stage diagnostic companies, emphasizing innovative and patient-centric technologies. Its portfolio includes a diverse range of capabilities, such as advanced sample collection methods, next-generation diagnostics, computational biology, and printed electronics. By focusing on these areas, Sapphiros aims to enhance the global accessibility of essential diagnostic results for consumers, thereby contributing to advancements in healthcare and diagnostic-related innovations.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company founded in 2017 that specializes in developing and commercializing a wearable microfluidic sensing platform. This innovative technology analyzes small droplets of sweat directly from the skin to provide insights into health, hydration, and athletic performance. The platform is designed to measure various biomarkers, including proteomics and inflammatory markers, allowing for personalized management of health and nutrition. Epicore's approach leverages over two decades of research in microfluidics and soft materials conducted by leading experts at Northwestern University. By offering a non-invasive and cost-effective solution, Epicore aims to enhance athletic performance and improve overall health monitoring for users.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

HelixBind is a biotechnology company located in Worcester, Massachusetts, founded in 2012. The company specializes in developing a pathogen identification platform that focuses on detecting bloodstream infections. This innovative platform enables rapid and precise identification of pathogens directly from whole blood specimens, eliminating the need for traditional blood culture methods. By facilitating swift detection, HelixBind's technology allows physicians to promptly implement targeted antimicrobial treatments and effectively monitor their efficacy throughout patient care.

The University of Vermont (UVM) is a public research university located in Burlington, Vermont, established in 1791. It is one of the oldest institutions of higher education in the United States and the fifth college founded in New England. UVM offers a diverse array of academic programs through its various schools and colleges, including the School of Business Administration, College of Agriculture and Life Sciences, College of Arts and Sciences, College of Communication, College of Medicine, College of Engineering and Mathematics, Graduate College, College of Nursing and Health Sciences, College of Education and Social Services, and School of Natural Resources. The university's campus spans 451 acres and features notable sites such as the historic University Green, the environmentally certified Dudley H. Davis Center, the Fleming Museum of Art, and the Gutterson/Patrick athletic complex. Additionally, the university is affiliated with Fletcher Allen Health Care, the largest hospital complex in Vermont, which is located adjacent to the campus and collaborates with the College of Medicine.

The University of Massachusetts Amherst is a public research and land-grant university that offers undergraduate, master's, and doctoral programs. It serves as the flagship campus of the University of Massachusetts system. The university has multiple academic departments and research facilities that support a range of disciplines.

HelixBind is a biotechnology company located in Worcester, Massachusetts, founded in 2012. The company specializes in developing a pathogen identification platform that focuses on detecting bloodstream infections. This innovative platform enables rapid and precise identification of pathogens directly from whole blood specimens, eliminating the need for traditional blood culture methods. By facilitating swift detection, HelixBind's technology allows physicians to promptly implement targeted antimicrobial treatments and effectively monitor their efficacy throughout patient care.

WindGap Medical is a biotech company that manufactures medical devices used to treat patients with severe allergies. The company develops auto-injectors that are filled with heat-stable epinephrine that enable physicians to inject it into a patient suffering from anaphylaxis due to an acute allergy attack. The company was established in 2011 and is headquartered in Somerville, Massachusetts.

Thetis Pharmaceuticals LLC is a biopharmaceutical company based in Branford, Connecticut, founded in 2011. The company specializes in developing immuno-resolving therapeutic solutions aimed at treating inflammatory bowel diseases and other inflammatory conditions. Utilizing its HEALER technology platform, Thetis Pharmaceuticals focuses on the pharmacology of lipids to create new and patented small molecule drugs that promote tissue regeneration and mitigate inflammation. Their research has advanced the development of resolvins, which act as potent agonists of inflammation resolution and tissue repair. These therapies are designed to counteract excessive inflammatory responses while preserving immune function, thereby enabling healthcare professionals to better manage patients' inflammatory conditions.

Skelmet Inc. is a Boston-based company that specializes in the design and production of custom head-worn products, including sunglasses, lenses, nose and temple pads, and carrying cases tailored for various sports such as running, cycling, skiing, golfing, sailing, and fishing. Founded in 2015, Skelmet utilizes advanced 3D Fit technology, which combines 3D scanning and 3D printing to create bespoke items that ensure a perfect fit for each individual user. The company has introduced products like the Falcon I bespoke sport sunglasses, which are lightweight and engineered for optimal performance and protection. Skelmet's offerings cater to active individuals seeking personalized and high-quality eyewear, and they are available for purchase through both physical stores and online platforms. Additionally, the company provides a mobile application that enables users to easily scan their heads and faces, facilitating the custom fitting process in under two minutes.

The University of Massachusetts Medical School (UMMS), founded in 1962 and located in Worcester, Massachusetts, is dedicated to providing affordable, high-quality medical education with a focus on increasing the number of primary care physicians in underserved areas. Recognized by U.S. News & World Report as a leading institution for primary care education, UMMS aims to enhance health and wellness in diverse communities both locally and globally. The university is committed to innovation in education, research, healthcare delivery, and public service, while its assets are managed by an executive team to support its mission effectively.

The University of Vermont (UVM) is a public research university located in Burlington, Vermont, established in 1791. It is one of the oldest institutions of higher education in the United States and the fifth college founded in New England. UVM offers a diverse array of academic programs through its various schools and colleges, including the School of Business Administration, College of Agriculture and Life Sciences, College of Arts and Sciences, College of Communication, College of Medicine, College of Engineering and Mathematics, Graduate College, College of Nursing and Health Sciences, College of Education and Social Services, and School of Natural Resources. The university's campus spans 451 acres and features notable sites such as the historic University Green, the environmentally certified Dudley H. Davis Center, the Fleming Museum of Art, and the Gutterson/Patrick athletic complex. Additionally, the university is affiliated with Fletcher Allen Health Care, the largest hospital complex in Vermont, which is located adjacent to the campus and collaborates with the College of Medicine.

If you reside in the Kingston, Rhode Island area and are looking for an undergraduate or graduate program for academic study, why not check out the University of Rhode Island? Programs available to choose from as a major include the interesting Animal and Veterinary Science, Business Administration, Civil and Environmental Engineering, Geology and Geological Oceanography, Human Development and Family Studies, International Engineering, Journalism, and Nursing, among many others. URI has a festive student life which includes both entertainment events and organizations which can help students get a leg up in the career search. Study abroad programs are offered during the summer and school year. There is also a strong Greek life, Student Senate, dining, and athletic programs. Other services include a counseling center and health services. If you qualify for financial aid like the Centennial and University Scholarships, your entire tuition may be covered. There are also grants and loans that can help cover tuition and other educational expenses. When it comes time to search for a job, the career service center can help students with writing resumes, interview preparation, meeting potential employers, and much more.

Aquinnah Pharmaceuticals, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, established in 2014. The company specializes in developing therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Aquinnah's research focuses on modulating neurodegenerative stress granules, which are thought to play a significant role in the pathology of ALS. Through its innovative approach, Aquinnah aims to address critical unmet medical needs in the treatment of these debilitating conditions.

Thetis Pharmaceuticals LLC is a biopharmaceutical company based in Branford, Connecticut, founded in 2011. The company specializes in developing immuno-resolving therapeutic solutions aimed at treating inflammatory bowel diseases and other inflammatory conditions. Utilizing its HEALER technology platform, Thetis Pharmaceuticals focuses on the pharmacology of lipids to create new and patented small molecule drugs that promote tissue regeneration and mitigate inflammation. Their research has advanced the development of resolvins, which act as potent agonists of inflammation resolution and tissue repair. These therapies are designed to counteract excessive inflammatory responses while preserving immune function, thereby enabling healthcare professionals to better manage patients' inflammatory conditions.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company focuses on developing and commercializing innovative silk biomaterial technologies. Its key product, the MIMIX microneedle platform, facilitates the transdermal delivery of vaccines and therapeutics. This sustained release patch technology allows for a controlled release of vaccines, mimicking the natural infection process to enhance immune response and effectiveness. Vaxess's patch is engineered for stability, eliminating the need for refrigeration, which enables shipping and application in low-resource settings. In addition to its vaccine delivery systems, Vaxess is also engaged in creating novel therapies aimed at oncology care and infectious diseases, ultimately striving to improve patient outcomes with reduced treatment burdens.

Thetis Pharmaceuticals LLC is a biopharmaceutical company based in Branford, Connecticut, founded in 2011. The company specializes in developing immuno-resolving therapeutic solutions aimed at treating inflammatory bowel diseases and other inflammatory conditions. Utilizing its HEALER technology platform, Thetis Pharmaceuticals focuses on the pharmacology of lipids to create new and patented small molecule drugs that promote tissue regeneration and mitigate inflammation. Their research has advanced the development of resolvins, which act as potent agonists of inflammation resolution and tissue repair. These therapies are designed to counteract excessive inflammatory responses while preserving immune function, thereby enabling healthcare professionals to better manage patients' inflammatory conditions.

Novo Biosciences develops cardiac drugs designed to reverse the life-threatening damage caused by heart attacks. Its drugs spur the body to heal itself by triggering powerful mechanisms of self-repair and regrowth that lie dormant in genes, enabling patients to regenerate damaged organs and tissues and live a healthier life. The company was founded in 2013 and is headquartered in Bar Harbor, Maine.

HelixBind is a biotechnology company located in Worcester, Massachusetts, founded in 2012. The company specializes in developing a pathogen identification platform that focuses on detecting bloodstream infections. This innovative platform enables rapid and precise identification of pathogens directly from whole blood specimens, eliminating the need for traditional blood culture methods. By facilitating swift detection, HelixBind's technology allows physicians to promptly implement targeted antimicrobial treatments and effectively monitor their efficacy throughout patient care.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

Aldatu Biosciences Inc. specializes in diagnostics for detecting drug resistance in antiretroviral treatments for HIV. The company utilizes its proprietary PANDAA technology, developed at Harvard University, to provide a robust solution for HIV genotyping. This platform enables healthcare providers to match patients with appropriate drugs, ultimately enhancing patient outcomes and reducing the overall costs associated with HIV care. Founded in 2014 and based in Cambridge, Massachusetts, Aldatu Biosciences is committed to advancing global health through innovative diagnostic solutions that address both infectious diseases and emerging health challenges. As a Public Benefit Corporation, the company focuses on improving patient care and healthcare cost efficiency worldwide.

EpiVax, Inc. is a biotechnology company specializing in the development of computational immunology tools to enhance immunotherapeutics. Based in Providence, Rhode Island, EpiVax provides a range of services including interactive protein screening, immunogenicity predictions for antibodies, and risk assessments of host cell protein contaminants. The company's offerings include high-throughput antibody immunogenicity reports, deimmunization solutions to mitigate immunogenic risks in protein therapeutics, and lab-based services such as HLA binding assays and T cell assays. Additionally, EpiVax is involved in the development of Tregitopes, which are sequences within monoclonal antibodies that activate regulatory T cells, as well as various epitope-based vaccines targeting diseases like smallpox and influenza. Founded in 1998, EpiVax leverages a blend of collaborative and internal programs to advance the field of immunology and provide safer immunotherapeutic options.

HelixBind is a biotechnology company located in Worcester, Massachusetts, founded in 2012. The company specializes in developing a pathogen identification platform that focuses on detecting bloodstream infections. This innovative platform enables rapid and precise identification of pathogens directly from whole blood specimens, eliminating the need for traditional blood culture methods. By facilitating swift detection, HelixBind's technology allows physicians to promptly implement targeted antimicrobial treatments and effectively monitor their efficacy throughout patient care.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapies that leverage the biology of DNA repair for cancer treatment and synthetic lethality in autoimmune diseases. The company utilizes its expertise in DNA damage response biology to create a pipeline of small molecule therapeutics aimed at selectively targeting vulnerabilities in cancer cells and inducing their self-destruction through DNA damage overload. Cyteir's lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, which is crucial for repairing double-strand DNA breaks. The company is dedicated to addressing a variety of hematological malignancies, solid tumors, and chronic autoimmune disorders through its integrated drug development platform. Founded in 2012, Cyteir is committed to advancing next-generation therapies that can improve patient outcomes in challenging disease states.

Sober Grid, Inc. operates a digital health platform that serves as a sober social network, facilitating connections among individuals recovering from substance use disorders. Launched in 2015 and headquartered in Boston, Massachusetts, the application is available on both Apple and Android devices and has been utilized over 20 million times across more than 170 countries. Developed in collaboration with researchers from Harvard Medical School and the University of Pennsylvania, Sober Grid employs a community-based approach to chronic disease management, incorporating evidence-based recovery tools and predictive analytics to assess relapse risk. The app features a GPS locator for users to find nearby sober individuals, along with direct messaging, a newsfeed, and access to certified coaching available 24/7. By combining technology with human connection, Sober Grid aims to improve health outcomes through real-time support and engagement, catering to a growing population of individuals in recovery.

Brown University Endowment is the investment arm of Brown University, located in Providence, Rhode Island, and founded in 1764. The endowment consists of various individual funds, including both donor-restricted and corporate-designated funds, aimed at maintaining the university's purchasing power and providing a stable financial resource for its operations. It invests across a diverse range of asset classes, including public equity, fixed income, real estate, commodities, and alternative markets. The endowment employs strategies such as long/short hedging to optimize its investment performance. Managed by the Brown University Investment Office under the oversight of the board of trustees, the endowment plays a crucial role in supporting the university’s commitment to exceptional education and research, serving approximately 8,000 students across its undergraduate, graduate, and medical programs.

TetraGenetics, Inc. is a biotechnology company focused on developing therapeutic proteins and vaccines for the biopharmaceutical industry. Established in 2004 and based in Arlington, Massachusetts, the company utilizes its proprietary TetraExpress system to produce recombinant human ion channel proteins and other complex biologics. TetraGenetics specializes in the production of eukaryotic membrane and secretory proteins, which are often difficult to express using conventional systems. Among its products is IchVax, a recombinant subunit vaccine aimed at preventing white-spot disease in freshwater fish. The company is also engaged in a strategic research and development collaboration with Imbrium Therapeutics L.P., aiming to address autoimmune diseases and provide solutions for ion channel-related conditions. TetraGenetics' technology enables rapid production of properly folded, functional transmembrane proteins, positioning the company as a valuable player in the development of novel therapeutics and vaccines for both human and animal health.

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for conditions such as traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer's disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selectively activating astrocytes. Its lead product, AST-004, is a novel small molecule designed for acute administration, aiming to protect and repair damaged neurons. Through its innovative approaches, Astrocyte Pharmaceuticals seeks to improve the recovery and well-being of patients suffering from brain injuries.

HelixBind is a biotechnology company located in Worcester, Massachusetts, founded in 2012. The company specializes in developing a pathogen identification platform that focuses on detecting bloodstream infections. This innovative platform enables rapid and precise identification of pathogens directly from whole blood specimens, eliminating the need for traditional blood culture methods. By facilitating swift detection, HelixBind's technology allows physicians to promptly implement targeted antimicrobial treatments and effectively monitor their efficacy throughout patient care.

The Vermont Genetics Network (VGN) is funded by a five-year, $16.5 million award from the National Center for Research Resources (NCRR), and is part of a National Institutes of Health (NIH) initiative called IDeA Networks of Biomedical Research Excellence (INBRE). Under the direction of Dr. Judith Van Houten, the VGN, which links scientists at Castleton State College, Johnson State College, Middlebury College, Norwich University and St. Michael's College to resources at UVM, is designed to provide funding for research, equipment and technology necessary to enhance competitiveness for national funding for genetics research. Other aims of the project include increasing the number of undergraduates who go on to biomedical careers from the baccalaureate colleges, to provide and support bioinformatics capability in the state, and to increase the diversity of biomedical scientists.

Aldatu Biosciences Inc. specializes in diagnostics for detecting drug resistance in antiretroviral treatments for HIV. The company utilizes its proprietary PANDAA technology, developed at Harvard University, to provide a robust solution for HIV genotyping. This platform enables healthcare providers to match patients with appropriate drugs, ultimately enhancing patient outcomes and reducing the overall costs associated with HIV care. Founded in 2014 and based in Cambridge, Massachusetts, Aldatu Biosciences is committed to advancing global health through innovative diagnostic solutions that address both infectious diseases and emerging health challenges. As a Public Benefit Corporation, the company focuses on improving patient care and healthcare cost efficiency worldwide.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company focuses on developing and commercializing innovative silk biomaterial technologies. Its key product, the MIMIX microneedle platform, facilitates the transdermal delivery of vaccines and therapeutics. This sustained release patch technology allows for a controlled release of vaccines, mimicking the natural infection process to enhance immune response and effectiveness. Vaxess's patch is engineered for stability, eliminating the need for refrigeration, which enables shipping and application in low-resource settings. In addition to its vaccine delivery systems, Vaxess is also engaged in creating novel therapies aimed at oncology care and infectious diseases, ultimately striving to improve patient outcomes with reduced treatment burdens.

Daktari Diagnostics, Inc. is a healthcare solutions company based in Cambridge, Massachusetts, founded in 2008. The company specializes in developing portable point-of-care diagnostic platforms aimed at improving disease management worldwide, particularly in resource-poor settings. Its key offerings include the Daktari Virology platform for detecting Hepatitis C and HIV, the Daktari InSight data management service that facilitates connectivity between diagnostic systems and healthcare providers, and the Daktari Sickle Cell solution, which enables the identification of infants with sickle cell disease from a single drop of blood. Daktari's products are designed to provide real-time diagnostic information while ensuring that critical data flows efficiently throughout the healthcare system, ultimately supporting better clinical outcomes and global disease elimination efforts.

First Light Diagnostics Inc. specializes in the development of automated medical diagnostic products aimed at detecting microbes responsible for healthcare-associated infections. The company is known for its benchtop MultiPath analyzer, which identifies both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses, making it suitable for hospital clinical microbiology laboratories. Its products address multiple applications, including the screening of blood, surgical, skin, and gastrointestinal infections. By offering rapid and cost-effective testing solutions, First Light Diagnostics meets the increasing demand for accurate diagnostics, which is essential for reducing hospital infection rates. The company's proprietary MultiPath detection technology combines the efficiency of advanced laboratory tests with affordability and ease of use. Founded in 2006 and based in Chelmsford, Massachusetts, First Light Diagnostics was previously known as First Light Biosciences until its name change in January 2019.

Boston Medical Center is a private, not-for-profit, academic medical center that provides its patients with trauma and emergency services. It is dedicated to providing accessible health care services to everyone. It also offers many outreach programs and services such as health screenings, smoking cessation, prevention food pantry, bWell center, and interpreter services. Boston Medical Center is based in Boston, Massachusetts.

The Miriam Hospital is a private, not-for-profit hospital at 164 Summit Avenue in Providence, in the U.S. state of Rhode Island. It is a major teaching affiliate of the Warren Alpert Medical School of Brown University.

Artaic, LLC is a Boston-based company that specializes in designing and fabricating custom tile work for both commercial and residential markets. Founded in 2007 by Ted Acworth, Artaic focuses on innovative mosaics that enhance the architecture and interior design sectors. Utilizing advanced technology, including computer-aided design software and a robotic mosaic assembly system, the company offers a wide range of applications, such as bathroom backsplashes, flooring, and public art installations. Artaic's approach allows for complete control over the color, material, and layout of its mosaics, enabling clients to achieve customized designs while minimizing costs. Additionally, the company provides installation services, further streamlining the process for its clientele.

Daktari Diagnostics, Inc. is a healthcare solutions company based in Cambridge, Massachusetts, founded in 2008. The company specializes in developing portable point-of-care diagnostic platforms aimed at improving disease management worldwide, particularly in resource-poor settings. Its key offerings include the Daktari Virology platform for detecting Hepatitis C and HIV, the Daktari InSight data management service that facilitates connectivity between diagnostic systems and healthcare providers, and the Daktari Sickle Cell solution, which enables the identification of infants with sickle cell disease from a single drop of blood. Daktari's products are designed to provide real-time diagnostic information while ensuring that critical data flows efficiently throughout the healthcare system, ultimately supporting better clinical outcomes and global disease elimination efforts.

Artaic, LLC is a Boston-based company that specializes in designing and fabricating custom tile work for both commercial and residential markets. Founded in 2007 by Ted Acworth, Artaic focuses on innovative mosaics that enhance the architecture and interior design sectors. Utilizing advanced technology, including computer-aided design software and a robotic mosaic assembly system, the company offers a wide range of applications, such as bathroom backsplashes, flooring, and public art installations. Artaic's approach allows for complete control over the color, material, and layout of its mosaics, enabling clients to achieve customized designs while minimizing costs. Additionally, the company provides installation services, further streamlining the process for its clientele.

Artaic, LLC is a Boston-based company that specializes in designing and fabricating custom tile work for both commercial and residential markets. Founded in 2007 by Ted Acworth, Artaic focuses on innovative mosaics that enhance the architecture and interior design sectors. Utilizing advanced technology, including computer-aided design software and a robotic mosaic assembly system, the company offers a wide range of applications, such as bathroom backsplashes, flooring, and public art installations. Artaic's approach allows for complete control over the color, material, and layout of its mosaics, enabling clients to achieve customized designs while minimizing costs. Additionally, the company provides installation services, further streamlining the process for its clientele.

ProThera Biologics, Inc. is a biotechnology company based in Providence, Rhode Island, founded in 2001 by Dr. Yow-Pin Lim and Dr. Douglas C. Hixson. The company focuses on developing human plasma proteins and therapeutic products that modulate inflammation through natural serine protease inhibitors. ProThera Biologics specializes in inter-alpha inhibitor proteins aimed at treating various inflammatory diseases, including sepsis, cancer, and anthrax intoxication. The company's innovative approach includes the development of integrated theranostic and therapeutic biomolecules that not only address inflammation but also assist in tissue repair, enhancing treatment efficacy for life-threatening conditions. ProThera Biologics has established a strategic partnership with ProMetic Life Sciences Inc. to further advance its research and product development.

EpiVax, Inc. is a biotechnology company specializing in the development of computational immunology tools to enhance immunotherapeutics. Based in Providence, Rhode Island, EpiVax provides a range of services including interactive protein screening, immunogenicity predictions for antibodies, and risk assessments of host cell protein contaminants. The company's offerings include high-throughput antibody immunogenicity reports, deimmunization solutions to mitigate immunogenic risks in protein therapeutics, and lab-based services such as HLA binding assays and T cell assays. Additionally, EpiVax is involved in the development of Tregitopes, which are sequences within monoclonal antibodies that activate regulatory T cells, as well as various epitope-based vaccines targeting diseases like smallpox and influenza. Founded in 1998, EpiVax leverages a blend of collaborative and internal programs to advance the field of immunology and provide safer immunotherapeutic options.

The University of New England is a health sciences university located in Biddeford, Maine, distinguished by its commitment to liberal arts education and innovative health programs. It hosts internationally recognized scholars and offers over 40 undergraduate, graduate, and professional degree programs, including Maine's only medical school. The university operates two campuses in Biddeford and Portland, providing interprofessional education through its various colleges, such as the College of Osteopathic Medicine and the College of Pharmacy. The institution actively manages an endowment fund, which invests donations to generate a reliable income source that supports its strategic initiatives and enhances educational opportunities for its students. The fund's assets are overseen by the university's executive management team, ensuring effective governance and alignment with the university's mission.

EpiVax, Inc. is a biotechnology company specializing in the development of computational immunology tools to enhance immunotherapeutics. Based in Providence, Rhode Island, EpiVax provides a range of services including interactive protein screening, immunogenicity predictions for antibodies, and risk assessments of host cell protein contaminants. The company's offerings include high-throughput antibody immunogenicity reports, deimmunization solutions to mitigate immunogenic risks in protein therapeutics, and lab-based services such as HLA binding assays and T cell assays. Additionally, EpiVax is involved in the development of Tregitopes, which are sequences within monoclonal antibodies that activate regulatory T cells, as well as various epitope-based vaccines targeting diseases like smallpox and influenza. Founded in 1998, EpiVax leverages a blend of collaborative and internal programs to advance the field of immunology and provide safer immunotherapeutic options.

The Jackson Laboratory conducts mammalian genetics research in the United States. It offers scientific services and genetic resources to laboratories internationally, and educates students of various ages through courses, internships, and programs. The company also provides scientific resources, techniques, software, and data to scientists internationally. It offers high school internships, pre and post-doctoral opportunities, and collaborative education programs. The company discovers genetic basis for preventing, treating, and curing human diseases in the areas of cancers, computational biology and bioinformatics, developmental and reproductive biology, immunology, metabolic diseases, and neurobiology. In addition, it offers mouse breeding and research services designed for mouse-based biomedical research community, such as breeding and colony management, cryopreservation and recovery, phenotyping and efficacy testing, genetic research services, and study-ready induced models. The Jackson Laboratory was founded in 1929 and is based in Bar Harbor, Maine. It has a facility in California.

Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for cancer and inflammatory diseases through its proprietary small molecule nucleotide platform. The company is advancing several key candidates, including SB 11285, an immunotherapeutic cyclic dinucleotide aimed at treating certain cancers, and novel STING antagonist compounds targeting autoimmune and inflammatory conditions. Additionally, Spring Bank is developing a platform for the targeted delivery of therapeutic payloads. The company has established a collaboration with Roche to investigate the co-administration of SB 11285. Founded in 2002 and headquartered in Hopkinton, Massachusetts, Spring Bank was previously known as Spring Bank Technologies, Inc. and underwent a name change in May 2008. The company was acquired by F-star Therapeutics Limited in a reverse merger transaction in November 2020.

EpiVax, Inc. is a biotechnology company specializing in the development of computational immunology tools to enhance immunotherapeutics. Based in Providence, Rhode Island, EpiVax provides a range of services including interactive protein screening, immunogenicity predictions for antibodies, and risk assessments of host cell protein contaminants. The company's offerings include high-throughput antibody immunogenicity reports, deimmunization solutions to mitigate immunogenic risks in protein therapeutics, and lab-based services such as HLA binding assays and T cell assays. Additionally, EpiVax is involved in the development of Tregitopes, which are sequences within monoclonal antibodies that activate regulatory T cells, as well as various epitope-based vaccines targeting diseases like smallpox and influenza. Founded in 1998, EpiVax leverages a blend of collaborative and internal programs to advance the field of immunology and provide safer immunotherapeutic options.

Selecta Biosciences, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in the research and development of nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company utilizes its proprietary ImmTOR immune tolerance platform to create targeted immunomodulatory nanoparticles that address undesired immune responses. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. The company collaborates with various partners, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development endeavors. Founded in 2007, Selecta Biosciences is committed to innovating therapeutic solutions in the biopharmaceutical landscape.

EpiVax, Inc. is a biotechnology company specializing in the development of computational immunology tools to enhance immunotherapeutics. Based in Providence, Rhode Island, EpiVax provides a range of services including interactive protein screening, immunogenicity predictions for antibodies, and risk assessments of host cell protein contaminants. The company's offerings include high-throughput antibody immunogenicity reports, deimmunization solutions to mitigate immunogenic risks in protein therapeutics, and lab-based services such as HLA binding assays and T cell assays. Additionally, EpiVax is involved in the development of Tregitopes, which are sequences within monoclonal antibodies that activate regulatory T cells, as well as various epitope-based vaccines targeting diseases like smallpox and influenza. Founded in 1998, EpiVax leverages a blend of collaborative and internal programs to advance the field of immunology and provide safer immunotherapeutic options.

First Light Diagnostics Inc. specializes in the development of automated medical diagnostic products aimed at detecting microbes responsible for healthcare-associated infections. The company is known for its benchtop MultiPath analyzer, which identifies both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses, making it suitable for hospital clinical microbiology laboratories. Its products address multiple applications, including the screening of blood, surgical, skin, and gastrointestinal infections. By offering rapid and cost-effective testing solutions, First Light Diagnostics meets the increasing demand for accurate diagnostics, which is essential for reducing hospital infection rates. The company's proprietary MultiPath detection technology combines the efficiency of advanced laboratory tests with affordability and ease of use. Founded in 2006 and based in Chelmsford, Massachusetts, First Light Diagnostics was previously known as First Light Biosciences until its name change in January 2019.

EpiVax, Inc. is a biotechnology company specializing in the development of computational immunology tools to enhance immunotherapeutics. Based in Providence, Rhode Island, EpiVax provides a range of services including interactive protein screening, immunogenicity predictions for antibodies, and risk assessments of host cell protein contaminants. The company's offerings include high-throughput antibody immunogenicity reports, deimmunization solutions to mitigate immunogenic risks in protein therapeutics, and lab-based services such as HLA binding assays and T cell assays. Additionally, EpiVax is involved in the development of Tregitopes, which are sequences within monoclonal antibodies that activate regulatory T cells, as well as various epitope-based vaccines targeting diseases like smallpox and influenza. Founded in 1998, EpiVax leverages a blend of collaborative and internal programs to advance the field of immunology and provide safer immunotherapeutic options.

EpiVax, Inc. is a biotechnology company specializing in the development of computational immunology tools to enhance immunotherapeutics. Based in Providence, Rhode Island, EpiVax provides a range of services including interactive protein screening, immunogenicity predictions for antibodies, and risk assessments of host cell protein contaminants. The company's offerings include high-throughput antibody immunogenicity reports, deimmunization solutions to mitigate immunogenic risks in protein therapeutics, and lab-based services such as HLA binding assays and T cell assays. Additionally, EpiVax is involved in the development of Tregitopes, which are sequences within monoclonal antibodies that activate regulatory T cells, as well as various epitope-based vaccines targeting diseases like smallpox and influenza. Founded in 1998, EpiVax leverages a blend of collaborative and internal programs to advance the field of immunology and provide safer immunotherapeutic options.

SmartCells, Inc. designs and develops insulin products. It offers SmartInsulin, a self regulating injectable formulation for treating diabetes. The company's polymer-based dosing technology is used for various applications, such as fertility, thyroid, and growth hormone deficiencies; treatments with poor compliance or therapeutic window issues, such as oncology; and drug-device combinations. SmartCells, Inc. was founded in 2003 and is based in Beverly, Massachusetts.

SmartCells, Inc. designs and develops insulin products. It offers SmartInsulin, a self regulating injectable formulation for treating diabetes. The company's polymer-based dosing technology is used for various applications, such as fertility, thyroid, and growth hormone deficiencies; treatments with poor compliance or therapeutic window issues, such as oncology; and drug-device combinations. SmartCells, Inc. was founded in 2003 and is based in Beverly, Massachusetts.